HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

HRYZ Biotech

Status and phase

Enrolling

Phase 1

Conditions

Carcinoma of Penis

Oropharyngeal Cancer

Anal Carcinoma

Carcinoma of Vulva

Cervical Cancer

Head and Neck Squamous Cell Carcinoma

Vagina Tumor

Treatments

Biological: HRYZ-T101 TCR-T Cell

Drug: Fludarabine + Cyclophosphamide

Study type

Interventional

Funder types

Industry

Identifiers

NCT05787535

HRYZ-T101-1002

Details and patient eligibility

About

A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of HRYZ-T101 TCR-T cell for HPV18 positive advanced solid tumor. The study will investigate DLT of HRYZ-T101 TCR-T cell injection.

Enrollment

17 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient must be willing to sign the informed consent form.
Age ≥18 years and ≤70 years.
Histologically-confirmed advanced metastatic or recurrent solid tumors with confirmed HPV18 infection and HLA-DRB1*09:01 allele.
Subjects who have failed at least first-line treatment in the past and lack effective treatment options.
ECOG performance status of 0-1.
Estimated life expectancy ≥ 3 months.
Patients must have at least one measurable lesion defined by RECIST 1.1.
Subjects with potential fertility must agree to use effective contraceptive methods during the whole trials period and at least 6 months after receiving HRYZ-T101 cell transfusion treatment.
Patients with any organ dysfunction as defined below:

Leukocytes≥3.0 x 10^9/L; 2) absolute neutrophil count ≤1.5 x 10^9/L; 3) blood platelets ≥75 x 10^9/L; 4) hemoglobin≥90g/L; 5) Serum albumin ≥ 3.0g/dL; 6) total bilirubin≤1.5×ULN; ALT/AST≤2.5×ULN; 7) Creatinine clearance ≥50mL/min; 8) INR≤1.5×ULN; APTT≤1.5×ULN; 9) LVEF≥50%; 10) SpO2≥92%.

Exclusion criteria

Organ transplanters and allogeneic cell transplanters.
Have a history of hypersensitivity to cyclophosphamide or fludarabine, and it is known that any ingredient used in the treatment of this study will produce allergic reactions.
Those who have undergone major surgery within 4 weeks before enrollment, and those who have received conventional chemotherapy, large-area radiotherapy, targeted therapy, endocrine therapy, immunotherapy or biological therapy, and Chinese herbal medicine and other anti-tumor treatment.
Have received live attenuated vaccine within 4 weeks before enrollment.
Subjects with clinical cardiac symptoms or diseases that cannot be well controlled.
The subject has active infection or fever more than 38.5 degrees of unknown cause during screening and before cell transfusion.
Subjects have any active autoimmune disease or history of autoimmune disease.
Subjects with other malignant tumors.
Patients with central nervous system metastasis.
Active, uncontrolled bacterial or fungal infection requiring systemic treatment.
Known HIV or syphilis infection, and/or active hepatitis B virus or hepatitis C virus infection.
It is planned to use immunosuppressive agents, or systemic corticosteroids, immunomodulators.
Have received any investigational drug within 4 weeks before enrollment, or have participated in another clinical study at the same time.
Pregnant or lactating subjects, or those who are unwilling to contraception during the test.
Known uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease or liver failure.
Other serious organic diseases and mental disorders.
Have received any gene therapy products before.
According to the judgment of the researcher, those who are not suitable for the group, such as poor compliance.